Keywords
PravastatinMedicineSimvastatinLovastatinFluvastatinTolerabilityCholesterolClinical trialHMG-CoA reductaseCoronary heart diseaseInternal medicineRandomized controlled trialStatinPharmacotherapyPharmacologyReductaseAdverse effect
Affiliated Institutions
Related Publications
Comparison of Once-Daily, niacin Extended-Release/lovastatin with standard doses of atorvastatin and simvastatin (the advicor versus other Cholesterol-Modulating agents trial evaluation [ADVOCATE])
This study compared the relative efficacy of a once-daily niacin extended-release (ER)/lovastatin fixed-dose combination with standard doses of atorvastatin or simvastatin, with...
Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR**STELLAR = Statin Therapies for Elevated Lipid Levels compared Across doses to Rosuvastatin. Trial)
The primary objective of this 6-week, parallel-group, open-label, randomized, multicenter trial was to compare rosuvastatin with atorvastatin, pravastatin, and simvastatin acros...
Once‐daily pravastatin in patients with primary hypercholesterolemia: A dose‐response study
Abstract This multicenter, double‐blind, placebo‐controlled study was conducted to evaluate dose‐response effects and safety of once‐daily administration of pravastatin, a new i...
Publication Info
- Year
- 1996
- Type
- review
- Volume
- 14
- Issue
- 1
- Pages
- 11-24
- Citations
- 104
- Access
- Closed
External Links
Social Impact
Altmetric
PlumX Metrics
Social media, news, blog, policy document mentions
Citation Metrics
104
OpenAlex
Cite This
Terje R. Pedersen,
Jonathan A. Tobert
(1996).
Benefits and Risks of HMG-CoA Reductase Inhibitors in the Prevention of Coronary Heart Disease A Reappraisal.
Drug Safety
, 14
(1)
, 11-24.
https://doi.org/10.2165/00002018-199614010-00003
Identifiers
- DOI
- 10.2165/00002018-199614010-00003